5-alpha Reductase Inhibitors
"5-alpha Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE.
| Descriptor ID |
D058891
|
| MeSH Number(s) |
D27.505.519.389.870.200 D27.505.696.399.450.855.200
|
| Concept/Terms |
5-alpha Reductase Inhibitors- 5-alpha Reductase Inhibitors
- 5 alpha Reductase Inhibitors
- Inhibitors, 5-alpha Reductase
- Reductase Inhibitors, 5-alpha
- Steroid 5-alpha-Reductase Inhibitors
- 5-alpha-Reductase Inhibitors, Steroid
- Inhibitors, Steroid 5-alpha-Reductase
- Steroid 5 alpha Reductase Inhibitors
- Testosterone 5-alpha-Reductase Inhibitors
- 5-alpha-Reductase Inhibitors, Testosterone
- Inhibitors, Testosterone 5-alpha-Reductase
- Testosterone 5 alpha Reductase Inhibitors
- 3-Oxo-5-alpha-Steroid 4-Dehydrogenase Inhibitors
- 3 Oxo 5 alpha Steroid 4 Dehydrogenase Inhibitors
- 4-Dehydrogenase Inhibitors, 3-Oxo-5-alpha-Steroid
- Inhibitors, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
|
Below are MeSH descriptors whose meaning is more general than "5-alpha Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "5-alpha Reductase Inhibitors".
This graph shows the total number of publications written about "5-alpha Reductase Inhibitors" by people in this website by year, and whether "5-alpha Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "5-alpha Reductase Inhibitors" by people in Profiles.
-
Differential Gene Expression in Post-Finasteride Syndrome Patients. J Sex Med. 2021 09; 18(9):1479-1490.
-
Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2020 06; 13(6):521-530.
-
5a-Reductase Inhibitor Use in Patients With Prostate Cancer. JAMA Intern Med. 2019 10 01; 179(10):1440.
-
Long-Term Effects of Finasteride on Prostate Cancer Mortality. N Engl J Med. 2019 01 24; 380(4):393-394.
-
Continued 5a-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. J Urol. 2019 01; 201(1):106-111.
-
Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride. Cancer Prev Res (Phila). 2019 02; 12(2):113-120.
-
Reduced Risk of Prostate Cancer With 5a-Reductase Inhibitors. J Natl Cancer Inst. 2018 11 01; 110(11):1159-1160.
-
Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2018 11 01; 110(11):1208-1215.
-
The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial. PLoS One. 2018; 13(10):e0204823.
-
Chemoprevention in Prostate Cancer: Current Perspective and Future Directions. Cold Spring Harb Perspect Med. 2018 10 01; 8(10).